Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31484872 | 0.86 | CA1 (0.47) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL1522738 | 0.81 | PKM (0.41) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL31172867 | 0.80 | STAT3 (0.43) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL30507895 | 0.80 | PTGS2 (0.43) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL2443529 | 0.79 | PTGS1 (0.40) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL31172561 | 0.79 | KDM4E (0.47) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL31525781 | 0.77 | CA1 (0.41) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL31536843 | 0.76 | CA2 (0.46) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL3600104 | 0.76 | CA2 (0.46) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL27643810 | 0.75 | PTGS2 (0.45) | CA1CA2CA9CA12PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-3334713-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | Memorial Sloan Kettering Cancer Center (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027845-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027841-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-3129767-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | Academia Sinica (TW) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015148915-A9 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016077581-A1 | ISOSTEVIOL TRIAZOLES AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-3003314-A2 | NOVEL COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2970504-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015148915-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-10-01 | — | — | WO | disclosed |
| EP-2831079-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2015-02-04 | — | — | EP | disclosed |
| WO-2014197313-A2 | NOVEL COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014160441-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
| EP-2512386-A1 | A GASTROINTESTINAL IMPLANT DEVICE | Vysera Biomedical Limited (IE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073970-A1 | A GASTROINTESTINAL IMPLANT DEVICE | VYSERA BIOMEDICAL LIMITED (IE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | CA1 3170/4885CA2 3912/4885CA9 3854/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | CA1 3170/4885CA2 3912/4885CA9 3854/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | CA1 2723/4885CA2 3408/4885CA9 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.